Gaithersburg-based biotech MedImmune entered an exclusive license agreement to work on vaccines targeting cancers caused by human papillomavirus, or HPV.
Under the agreement, announced Monday, MedImmune — the biologics research and development arm of U.K. pharmaceutical giant AstraZeneca (NYSE: AZN) – will collaborate with immunotherapy company Inovio Pharmeuticals. Inovio’s “INO-3112” immunotherapy generates killer T-cell responses to destroy tumors associated with HPV. It is in Phase I and II clinical trials for cervical, head and neck cancers.
{iframe}http://www.bizjournals.com/washington/blog/2015/08/medimmune-inks-27-5-million-licensing-deal-on.html?ana=e_du_pap&s=article_du&ed=2015-08-10&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1439238136{/iframe}